BR112023003622A2 - Proteína de pico recombinante, polinucleotídeo, vetor e uso do polinucleotídeo - Google Patents

Proteína de pico recombinante, polinucleotídeo, vetor e uso do polinucleotídeo

Info

Publication number
BR112023003622A2
BR112023003622A2 BR112023003622A BR112023003622A BR112023003622A2 BR 112023003622 A2 BR112023003622 A2 BR 112023003622A2 BR 112023003622 A BR112023003622 A BR 112023003622A BR 112023003622 A BR112023003622 A BR 112023003622A BR 112023003622 A2 BR112023003622 A2 BR 112023003622A2
Authority
BR
Brazil
Prior art keywords
polynucleotide
vector
recombinant
present
antibody production
Prior art date
Application number
BR112023003622A
Other languages
English (en)
Inventor
Kang Chang-Yuil
Shin Seung-Phil
Shin Kwang-Soo
Oh Tae-Gwon
Original Assignee
Cellid Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellid Co Ltd filed Critical Cellid Co Ltd
Publication of BR112023003622A2 publication Critical patent/BR112023003622A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PROTEÍNA DE PICO RECOMBINANTE, POLINUCLEOTÍDEO, VETOR E USO DO POLINUCLEOTÍDEO. A presente invenção se refere a uma proteína de pico recombinante de coronavírus inovadora, um polinucleotídeo que codifica a mesma, um vetor que compreende o polinucleotídeo e uma vacina para prevenir ou tratar uma infecção de coronavírus que compreende o vetor. A proteína de pico recombinante de coronavírus da presente invenção é estável e, portanto, não é facilmente decomposta em células e ativa efetivamente células imunes, resultando, assim, em uma alta quantidade de produção de anticorpo e reatividade de célula T. Foi confirmado que o vetor da presente invenção exibe um alto nível de expressão de antígeno e, dessa forma, tem uma alta quantidade de produção de anticorpo e reatividade de célula T, tem um longo período de produção de anticorpo e período de expressão e não mostra toxicidade de fígado. Consequentemente, o vetor da presente invenção pode ser usado de forma útil como uma vacina para prevenir ou tratar uma infecção de coronavírus.
BR112023003622A 2020-08-27 2021-08-27 Proteína de pico recombinante, polinucleotídeo, vetor e uso do polinucleotídeo BR112023003622A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020200108276 2020-08-27
KR20200152184 2020-11-13
PCT/KR2021/011512 WO2022045827A1 (ko) 2020-08-27 2021-08-27 신규한 코로나바이러스 재조합 스파이크 단백질, 이를 코딩하는 폴리뉴클레오티드, 상기 폴리뉴클레오티드를 포함하는 벡터 및 상기 벡터를 포함하는 코로나바이러스감염증 예방 또는 치료용 백신

Publications (1)

Publication Number Publication Date
BR112023003622A2 true BR112023003622A2 (pt) 2023-03-28

Family

ID=80355513

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023003622A BR112023003622A2 (pt) 2020-08-27 2021-08-27 Proteína de pico recombinante, polinucleotídeo, vetor e uso do polinucleotídeo

Country Status (7)

Country Link
US (1) US20230293670A1 (pt)
EP (1) EP4205761A4 (pt)
JP (1) JP2023543387A (pt)
KR (1) KR20220027785A (pt)
CN (1) CN116348136A (pt)
BR (1) BR112023003622A2 (pt)
WO (1) WO2022045827A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230145859A (ko) 2022-04-11 2023-10-18 단국대학교 천안캠퍼스 산학협력단 SARS-CoV 슈도타입화된 복제-가능 레트로바이러스 벡터 시스템
GB2624391A (en) * 2022-11-15 2024-05-22 Univ Cape Town Recombinant LSDV vectored bovine coronavirus antigen constructs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4691495B2 (ja) * 2004-07-15 2011-06-01 一般財団法人化学及血清療法研究所 コロナウイルススパイクｓ１融合蛋白及びその発現ベクター
CN111218459B (zh) * 2020-03-18 2020-09-11 中国人民解放军军事科学院军事医学研究院 一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗
WO2021194826A2 (en) * 2020-03-24 2021-09-30 Icahn School Of Medicine At Mount Sinai Recombinant sars-cov-2 spike protein and uses thereof
KR20230008801A (ko) * 2020-05-07 2023-01-16 트랜슬레이트 바이오 인코포레이티드 Sars-cov-2 항원을 암호화하는 최적화된 뉴클레오티드 서열
JP2023525785A (ja) * 2020-05-11 2023-06-19 ヤンセン ファーマシューティカルズ，インコーポレーテッド 安定化コロナウイルススパイクタンパク質をコードするｒｎａレプリコン

Also Published As

Publication number Publication date
US20230293670A1 (en) 2023-09-21
EP4205761A1 (en) 2023-07-05
KR20220027785A (ko) 2022-03-08
EP4205761A4 (en) 2024-05-29
WO2022045827A1 (ko) 2022-03-03
JP2023543387A (ja) 2023-10-16
CN116348136A (zh) 2023-06-27

Similar Documents

Publication Publication Date Title
BR112023003622A2 (pt) Proteína de pico recombinante, polinucleotídeo, vetor e uso do polinucleotídeo
BR112022003543A2 (pt) Inibidores de kras g12
BR112021023359A2 (pt) Inibidores de g12c de kras e usos dos mesmos
BR112018001640A2 (pt) combinação de antagonista da pd-1 com um inibidor de egfr
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112019004560A2 (pt) tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv
BR112015027288A8 (pt) uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit
BR112022002059A2 (pt) Formas sólidas de um inibidor de hpk1
BR112015007742B1 (pt) composto, composição farmacêutica, e, uso do referido composto
AR101504A1 (es) Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CL2021002646A1 (es) Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicosactivos
BR112017019343A2 (pt) uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas
AR108889A1 (es) Combinaciones para el tratamiento del cáncer
BR112022022401A2 (pt) Terapia de combinação tripla para aumentar o extermínio de células cancerígenas em cânceres com baixa imunogenicidade
CL2020001349A1 (es) Compuestos, composición y uso de los mismos como moduladores de la expresión de pcsk9. (divisional solicitud 201902574)
CO2022000270A2 (es) Inhibidores de enzimas
BR112022010319A2 (pt) Uso de bi853520 no tratamento de câncer
CL2021001976A1 (es) Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular
CO2023001561A2 (es) Combinaciones para el tratamiento de cáncer
BRPI0514724A (pt) inibidores da enzima hiv integrase
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
BR112023000220A2 (pt) Formulações de longa ação
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante